Clinical Trial: A Randomized Controlled Trial: Fuzheng Yangxin Formula for ERAS After CABG

U.S., Aug. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07781436) titled 'A Randomized Controlled Trial: Fuzheng Yangxin Formula for ERAS After CABG' on Aug. 04.

Brief Summary: This study aims to evaluate the efficacy and safety of Fuzheng Yangxin Formula (FZYXF) in the treatment of qi-yin deficiency syndrome after coronary artery bypass grafting (CABG), formulate an integrated Chinese and Western medicine rehabilitation protocol, develop special proprietary Chinese medicines for postoperative patients, establish a postoperative rehabilitation database, and promote the standardized application and achievement transformation of integrated Chinese and Western medicine therapy in cardiac surgery.

Study Star...